Metabolic Acidosis in CKD: Pathogenesis, Adverse Effects, and Treatment Effects
International Journal of Molecular Sciences · 10.05.2024 · 25 (10) · 5187
DOI: 10.3390/ijms25105187 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 10.05.2024. Verfasst von Kalani L Raphael. Beteiligte Einrichtung: Division of Nephrology & Hypertension, Department of Internal Medicine, University of Utah, Salt Lake City, UT 84112, USA. Hauptthemen laut MEDLINE: Acidosis, Renal Insufficiency, Chronic, Sodium Bicarbonate. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CSRD VA, NIDDK NIH HHS, National Institute of Health.
Abstract (Originalsprache)
Metabolic acidosis is a frequent complication of chronic kidney disease and is associated with a number of adverse outcomes, including worsening kidney function, poor musculoskeletal health, cardiovascular events, and death. Mechanisms that prevent metabolic acidosis detrimentally promote further kidney damage, creating a cycle between acid accumulation and acid-mediated kidney injury. Disrupting this cycle through the provision of alkali, most commonly using sodium bicarbonate, is hypothesized to preserve kidney function while also mitigating adverse effects of excess acid on bone and muscle. However, results from clinical trials have been conflicting. There is also significant interest to determine whether sodium bicarbonate might improve patient outcomes for those who do not have overt metabolic acidosis. Such individuals are hypothesized to be experiencing acid-mediated organ damage despite having a normal serum bicarbonate concentration, a state often referred to as subclinical metabolic acidosis. Results from small- to medium-sized trials in individuals with subclinical metabolic acidosis have also been inconclusive. Well-powered clinical trials to determine the efficacy and safety of sodium bicarbonate are necessary to determine if this intervention improves patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology & Hypertension, Department of Internal Medicine, University of Utah, Salt Lake City, UT 84112, USA.
- Medicine Section, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT 84148, USA.
Förderung
- CSRD VA
- NIDDK NIH HHS
- National Institute of Health
- United States Department of Veterans Affairs
Zitieren
APA
Raphael, K. L. (2024). Metabolic Acidosis in CKD: Pathogenesis, Adverse Effects, and Treatment Effects. International Journal of Molecular Sciences, 25(10), 5187. https://doi.org/10.3390/ijms25105187
Vancouver
Raphael KL. Metabolic Acidosis in CKD: Pathogenesis, Adverse Effects, and Treatment Effects. International Journal of Molecular Sciences. 2024;25(10):5187. doi:10.3390/ijms25105187
BibTeX
@article{Raphael2024,
author = {Raphael, Kalani L},
title = {Metabolic Acidosis in CKD: Pathogenesis, Adverse Effects, and Treatment Effects},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {10},
pages = {5187},
doi = {10.3390/ijms25105187}
}
EUVIMED